Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.
TL;DR
Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is effective for treating relapsed or refractory B-cell lymphoma; however, its outcomes remain heterogeneous. We conducted a nationwide retrospective registry study in Japan to assess whether pretreatment body mass index (BMI) influences outcomes after CD19-directed CAR T-cell therapy. Among 944 patients with relapsed or refractory B-cell lymphoma treated between 2019 and 2024, BMI was categorized as Low (<18.5 kg/m²; n = 166), Normal (18.5 to 24.9 kg/m²; n = 619), or High (≥25 kg/m²; n = 159). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse or progression (CIR), non-relapse mortality (NRM), and CAR T-cell-related toxicities. Six-month OS rates in the low, normal, and high BMI groups were 73.2%, 83.7%, and 89.3%, respectively (P < .01), and corresponding PFS was 62.3%, 75.6%, and 77.7% (P < .01). CIR was more frequent in the Low-BMI group, whereas NRM did not differ significantly across groups. In the overall cohort, Low-BMI was associated with shortened OS and PFS and higher CIR in multivariable analyses. In a complete-case sensitivity analysis restricted to patients with available disease status data at the time of infusion, these associations were attenuated after adjusting for disease status. Severe CAR T-cell-related toxicities were comparable across BMI groups. Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.